维普期刊资源整合服务平台（V6.5）

36篇 您的检索式：作者名="DOEBELE RC"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer显示文摘	Doebele RC Lu X Sumey C	2012	Cancer2012，118，：	1
2	Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epider- mal growth factor receptor显示文摘	Berge EM Doebele RC	2014	Semin Oneol2014，41，1：	1
3	A novel interplay between Epae/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signal- regulated kinase 5 ( MEK5/ERK5 ) regulates thrombospondin to control anglo- genesis 显示文摘	Doebele RC Schulze-Hoepfner Fr Hong J	2009	Blood2009，114，：	1
4	Mechanisms ofresistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer显示文摘	Doebele RC Pilling AB Aisner DL	2012	Clin Cancer Res2012，18，5：	1
5	Re-examination of maintenance therapy in nonsmall cell lung cancer with the advent of new anti-cancer agents显示文摘	Berge EM Doebele RC	2013	Drugs2013，73，6：	1
6	Mechanisms of resist-ance to crizotinib in patients with ALK gene rearranged non-smallcell lung cancer 显示文摘	Doebele RC Pilling AB Aisner DL	2012	Clin Cancer Res2012，18，5：	1
7	Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsqua- mous, advanced/metastatic non-small cell lung cancer显示文摘	Doebele RC Splgel D Tehfe M	2015	Cancer2015，121，6：	1
8	A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer 显示文摘	Doebele RC Conkling P Traynor AM	2012	Annals of Oncology2012，23，8：	1
9	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small-cell lung cancer显示文摘	Doebele RC Pilling AB Aisner DL	2012	Clin Cancer Res2012，18，5：	1
10	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer显示文摘	Doebele RC Pilling AB Aisner DL		0，，05：	1
11	Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer显示文摘	Doebele RC Pi Aisner DL	2012	Clin Cancer Res2012，18，5：	1
12	Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsqua- non-small cell lung cancer显示文摘	Doebele RC Spigel D Tehfe M	2015	Cancer2015，121，6：	1
13	Crizotinib for the treatment of patients with advanced non-small cell lung cancer显示文摘	Bowles DW Weickhardt AJ Doebele RC	2012	Drugs of Today2012，48，4：	1
14	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer 显示文摘	Doebele RC Pilling AB Aisner DL	2012	Clin Cancer Res2012，18，5：	1
15	A nice problem to have: when ALK inhibitor therapy works better than expected 显示文摘	Doebele RC	2014	J Thorac Oncol2014，9，4：	1
16	Treating ALK-positive lung cancer--early successes and future challenges显示文摘	Camidge DR Doebele RC		0，，05：	1
17	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer显示文摘	Doebele RC Pilling AB Aisner DL		0，，：	1
18	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer显示文摘	Doebele RC Pilling AB Aisner DL	2012	Clin Cancer Res2012，18，5：	1
19	Treating ALK -positive lung cancer- early successes and future challenges 显示文摘	Camidge DR Doebele RC	2012	Nat Rev Clin Onco12012，9，5：	1
20	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer显示文摘	Doebele RC Pilling AB Aisner DL		0，，05：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示